QUICK ANSWER · AEO / GEO
Rybelsus is an oral semaglutide product. The reviewed Thai FDA record lists glycaemic control in adults with type 2 diabetes and cardiovascular risk reduction in a defined high-risk adult population. Its product identity and indications should not be replaced with those of Ozempic or Wegovy.
THAI INDICATION BOUNDARY
What does the reviewed Thai record indicate?
Glycaemic control in adults with type 2 diabetes, alongside diet and exercise.
Reduction of major cardiovascular events in defined high-risk adults with type 2 diabetes.
PRODUCT IDENTITY
Rybelsus is not every Semaglutide product
- The product name, registration, formulation and authorised holder must match.
- An identical active ingredient does not make indications interchangeable between brands.
- Unofficial packaging or an unverified label does not establish identity, quality or approval.
SAFETY BOUNDARY
Prescription and high-risk context
Contraindications, gastrointestinal effects, pancreatitis and gallbladder risks, dehydration, interactions and individual medical history require current product information and a qualified professional.
- Population-level study outcomes do not predict an individual's response.
- Safety information must match the exact product and current Thai documentation.
- This page does not provide dosage, administration or injection instructions.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Rybelsus?
Rybelsus is a product containing Semaglutide. Its identity, formulation, jurisdiction and indications must be assessed as a specific product.
Is Rybelsus registered in Thailand?
PrimeCoreBio found the reviewed Thai product record 1C 15171/64 (NBC). Regulatory status is time-sensitive and should be checked against the current official record.
Does this page provide dosage or injection instructions?
No. It contains no price, purchasing, dosage, administration or injection protocol and does not replace professional medical advice.
SOURCE TRANSPARENCY
Primary and supporting sources
- อย. ไทย — ระเบียน RybelsusPrimary regulatory record · https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug.aspx?Newcode_U=U1DR1C1072641517111C
- อย. ไทย — รายการผลิตภัณฑ์ semaglutideOfficial product database · https://ndi.fda.moph.go.th/drug_info_corporation/corp/12516
- Semaglutide Evidence ProfilePrimeCore evidence synthesis · /molecules/semaglutide
Educational information only. Not diagnosis, treatment, prescribing, dosage, administration, injection guidance or individual medical advice.